You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
先瑞達醫療-B(06669.HK)香港公開發售獲654.51倍認購 上限定價每股23.8港元
格隆匯 08-23 06:46

格隆匯8月23日丨先瑞達醫療-B(06669.HK)發佈公吿,公司全球發售6863.3萬股股份,其中香港發售股份3431.8萬股,國際發售股份3431.5萬股,另有15%超額配股權;發售價已釐定為每股發售股份23.80港元,每手買賣單位1000股;摩根士丹利及中金公司為聯席保薦人;預期股份將於2021年8月24日於聯交所主板掛牌上市。

根據國際發售初步提呈發售的股份已獲超額認購,相當於根據國際發售初步可供認購的股份總數約4.86倍。根據香港公開發售初步提呈發售的香港發售股份獲非常大幅超額認購。合共接獲310,661份有效申請,認購合共44.93億股香港發售股份,相當於根據香港公開發售初步可供認購的股份總數約654.51倍。

基於每股發售股份發售價為23.80港元,根據相關基石投資協議,公司的基石投資者已認購合共3425.9萬股股份,合共相當於緊隨全球發售完成後公司已發行股本約10.93%及全球發售的發售股份數目約49.92%,在兩種情況下均假設超額配股權並無獲行使。

根據每股發售股份發售價23.80港元,公司自全球發售收取的所得款項淨額估計約15.29億港元(假設超額配股權並無獲行使)。倘若超額配股權獲悉數行使,則公司將就超額配股權獲行使而將予配發及發行的1029.4萬股額外股份收取額外所得款項淨額約2.364億港元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account